Cablivi for Acquired Thrombotic Thrombocytopenic purpura

Researchers investigated the timing of hypertension diagnosis, exploring how it’s associated with medication prescribing and long-term cardiovascular outcomes.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

The Cut Hypertension Program operates in barbershops across the Bay Area in California. The program’s lead pharmacist joined us to discuss main themes and goals of the new initiative.

The therapy is now the first and only oral on demand treatment option for the condition.

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.